Dave Clarke
Neurology with Special Qualifications in Child Neurology · Austin, TXNPI 1871550772
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,618 of the $17,916 with a category attached, or 70.4%. Neurelis, Inc. accounts for 62.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $7,483 and has fallen 65.3% since, to $2,599 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $245.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$11K
- Aquestive Therapeutics, Inc.$3K
- Monteris Medical Corporation$2K
- UCB, Inc.$1K
- Livanova USA, Inc.$833
- Supernus Pharmaceuticals, Inc.$78
- plus $388 from 11 others
Across 89 payments — averaging $1207.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$65K
- UCB SA$42K
What the payments were for
- Consulting fees$12,61870%
- Travel & lodging$1,5178%
- Food & beverage$3,76921%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 21 | $11,181 |
| Aquestive Therapeutics, Inc. | 3 | $2,694 |
| Monteris Medical Corporation | 2 | $1,664 |
| UCB, Inc. | 13 | $1,077 |
| Livanova USA, Inc. | 14 | $833 |
| Supernus Pharmaceuticals, Inc. | 5 | $78 |
| Jazz Pharmaceuticals Inc. | 1 | $65 |
| Upsher-smith Laboratories LLC | 2 | $57 |
| Greenwich Biosciences, Inc. | 3 | $54 |
| GE HealthCare | 1 | $44 |
| Eisai Inc. | 1 | $43 |
| Biocodex, Inc. | 1 | $33 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $18 |
| Zogenix Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$10,847
- SYMPAZAN$2,694
- Neuroblate$1,600
- Fintepla$236
- VNS Therapy$224
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$216
How this compares
$17,916 in reported general payments places this provider in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OnfiClobazam | 23 | $58,122 |
| EpidiolexCannabidiol (Cbd) | 11 | $54,190 |
| Lacosamide | 15 | $3,477 |
| Lamotrigine ErLamotrigine | 13 | $2,757 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,042 |
| Guanfacine Hcl ErGuanfacine Hcl | 13 | $998 |
| Fluticasone Propionate | 17 | $611 |
| Clonazepam | 16 | $379 |
| Valproic AcidValproic Acid (As Sodium Salt) | 16 | $377 |
| Oxcarbazepine | 11 | $287 |
| Lamotrigine | 12 | $153 |
| Sertraline Hcl | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Austin
- Shelly ReardonAustin$17K
- Samantha IrwinAustin$7K
- Jinfon OngAustin$4K
- Holly KeeleyAustin$3K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.